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Adjuvant radiotherapy (ART) after prostatectomy for patients with high-risk features 
[extracapsular extension (ECE), seminal vesicle invasion (SVI), and positive margin] has 
been shown to be associated with improved biochemical disease-free survival in three 
large randomized trials and with improved overall survival in one. Similarly, salvage radio-
therapy (SRT) can effectively achieve biochemical control in a significant proportion of 
patients with a rising PSA after surgery. Nonetheless, both approaches of postoperative 
RT remain highly underutilized. This might be partly due to concerns with overtreatment 
inherent to adjuvant approaches, and/or hesitance about causing radiation toxicities and 
their subsequent effects on the patient’s quality of life. Herein, we review the literature 
lending evidence to these arguments. We show recent series of ART/SRT and their low 
rates of acute and long-term toxicities, translating only in transient decline in quality-of-life 
(QoL) outcomes. We conclude that concerns with side effects should not preclude the 
recommendation of an effective and curative-intent therapy for men with prostate cancer 
initially treated with radical surgery.
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inTRODUCTiOn: ROLe OF ADJUvAnT AnD SALvAGe 
RADiOTHeRAPY AFTeR PROSTATeCTOMY AnD THe 
UnDeRUTiLiZATiOn PROBLeM
There were approximately 220,800 new cases of prostate cancer (PCa) diagnosed only in the US in 
2015, with 27,540 patients dying from the disease (1). According to a recent analysis based on SEER 
data, 90% of prostate cancer cases in the US are diagnosed in localized stages, and 40% of these 
are treated with radical prostatectomy (2). After surgery alone, 30–40% of patients will experience 
biochemical failure (3–5), and one-third of recurrent cases will be subsequently diagnosed with 
metastatic disease (6). Nonetheless, death from prostate cancer remains infrequent, and cancer-
specific survival rates are above 90% after 15 years of surgery alone (5).
In order to decrease the risk of biochemical failure, particularly in patients with high-risk fea-
tures (including positive surgical margins, high grade disease, and/or pT3-stage) (7), postoperative 
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radiotherapy has been studied and shown efficacious. Three 
randomized trials from cooperative groups (SWOG-8794, 
EORTC 22911, and ARO 96-02) have demonstrated significant 
biochemical disease-free survival improvement with adjuvant 
radiotherapy for patients with high-risk features (8–11). 
Moreover, one of these trials showed superior overall survival 
in the radiation arm (11). Given these benefits, adjuvant 
radiotherapy in high-risk patients has been endorsed and rec-
ommended by practice guidelines from leading European and 
North American societies (12–14).
In patients presenting with biochemical recurrence (rising 
PSA) after prostatectomy, salvage radiation has been reported to 
achieve an overall biochemical response rate of 50%, translating 
into a threefold increase in prostate cancer specific survival (15). 
However, long-term disease control rates are highly variable, 
ranging from 10 to 40%, mostly due to the intrinsic patients’ 
heterogeneity in this high-risk population. To date, there is lack 
of robust predictive markers to identify those with PSA increase 
due to local recurrence (who are likely to benefit from salvage 
radiation) from those with already microscopic distant spread 
(in whom further local therapies is likely futile) (16, 17). At pre-
sent, no prospective study has directly compared ART vs. SRT 
approaches. Although such efforts are currently underway, the 
optimal postoperative RT timing conundrum remains a topic of 
controversy (18).
Despite the demonstrated benefits of both adjuvant and salvage 
radiotherapy, these treatments remain strikingly underutilized, 
with <15% of eligible patients with high-risk features receiving 
radiotherapy across different jurisdictions (19–25). Moreover, 
during the last decade, the absolute utilization rates have not 
significantly changed despite the publication of the three large 
ART randomized trials (21, 24, 26), notwithstanding the fact that 
recommendation for the use of adjuvant radiation has increased 
(25). This discrepancy between evidence and practice is more 
pronounced in older patients, plausibly due to the uncertainty 
about treatment benefits in the context of a shorter life span and/
or higher comorbidities (21).
To explain this underutilization, some plausible reasons have 
been suggested in relation to the pivotal trials’ design and out-
comes. Related to design, the comparison of ART with observa-
tion instead of early SRT (19), not ascertaining the use or timing 
of SRT in the observation arm, and the inclusion of patients 
with detectable PSA pre-ART (27) have been mainly discussed. 
Regarding outcomes, particularly the absence of survival benefit 
in two of the trials has been highlighted, with improvements 
shown only in SWOG study, which could have been confounded 
by comorbidities in the control group (28). Additionally, 
physician’s specialty appears also to influence ART/SRT use, as 
demonstrated by urologists being less likely to recommend it 
compared to radiation oncologists (29, 30). Patient factors, such 
as age, comorbidities, and life expectancy estimates, have also 
been suggested to influence endorsement of post-prostatectomy 
radiation (21).
However, current literature has mostly focused on two major 
reasons for withholding or deferring the use of postoperative 
radiotherapy, namely, concerns with overtreatment and radiation 
toxicities with their subsequent impact on patient’s quality of life. 
To better understand the delay in practice change, herein, we 
summarize the literature focusing on these two potential factors. 
The evidence presented here could also serve to guide treatment 
individualization and shared decision-making between physi-
cians and patients regarding curative-intent adjuvant and salvage 
radiotherapy after radical prostatectomy.
Avoiding Overtreatment or Favoring 
Undertreatment? nuances until 
Superiority (or non-inferiority) of SRT is 
Proven
Although the bulk of evidence supports the use of immediate 
postoperative radiation, its proper timing is a matter of debate 
(28) mainly due to the concerns related to the possibility of 
overtreatment with early adjuvant radiation. A considerable pro-
portion of high-risk patients achieve good disease control with 
surgery alone, with slightly over half of them remaining free from 
biochemical failure at 5 years (10, 31). In patients with adverse 
pathological features, such as ECE, positive margins, and SVI, the 
10-year progression-free probability can be as high as 71, 44, and 
37%, respectively (32, 33). Therefore, the alternative concept of 
delaying radiotherapy to the time of recurrence (i.e., rising PSA) 
has been proposed by some as an effective method to provide the 
same results while avoiding the intrinsic overtreatment risk of 
adjuvant approaches (16).
This treatment strategy, at present time, is supported by ret-
rospective evidence (34), and as the core, assumes that SRT or 
delayed ART could be as effective as immediate ART (26). Indeed, 
a pooled analysis of 10 SRT studies has yielded bRFR rates similar 
to historic reports of adjuvant radiation (71 vs. 67–74%, respec-
tively) (34). However, this indirect comparison in the absence of 
randomized prospective data cannot safely answer whether early 
salvage is really equivalent to adjuvant radiation. In fact, matched 
group analyses have shown superiority of adjuvant over salvage 
radiotherapy with regards to freedom from biochemical failure 
(35–37). Solving this clinical conundrum is the objective of ongo-
ing phase III trials, including RADICALS (34), RAVES (35), and 
GETUG-17 (http://ClinicalTrials.gov identifier NCT00667069), 
from which informative results will likely be available in the 
upcoming decade.
Although SRT approaches might be inferior to ART in general, 
within the former, earlier rather than delayed salvage has shown 
superior outcomes. The aforementioned pooled analysis on 
retrospective studies demonstrates improved 5-year biochemi-
cal relapse-free survival with early salvage compared to delayed 
salvage radiation, with improved outcomes in those patients with 
a PSA level of <0.5 ng/ml. Other studies have suggested differ-
ent threshold values (34, 38, 39). Acknowledging that within 
SRT approach, earlier salvage renders more favorable results, 
the comparison with adjuvant radiation remains unclear given 
the lack of prospective studies. In addition, clinically applicable 
and validated PSA thresholds have been hard to determine. The 
available cutoff points below which SRT is assumed to be equal 
to ART mostly represent study-specific statistical considerations 
and might not be used to guide clinical practice until properly 
validated in a prospective fashion.
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Intention to avoid potential overtreatment inherent to adjuvant 
approaches is a longing that is not exclusive to prostate cancer 
(40), and one of the principles of personalized cancer treatments 
is to tailor management to each patient’s disease and individual 
unique characteristics. When robust and consistent evidence sup-
ports the use of adjuvant treatment, the goal for avoiding over-
treatment should be to precisely identify those patients in whom 
the treatment is futile, without precluding a priori a significant 
proportion of patients to derive benefit from such therapy. This 
requires prospective studies with sufficient follow-up (41), which 
at present are lacking in postoperative prostate cancer setting. 
A similar scenario was experienced in determining the role of 
axillary node dissection in breast cancer patients with positive 
sentinel node biopsy. Almost 7000 patients were randomized in 
three separate trials [IBCSG 23-01 (42), AOCSOG Z0011 (43), 
and EORTC 10981-22023-AMAROS (44)] before a conclusion 
could be reached regarding the subset of patients where elimina-
tion of axillary dissection is safely warranted.
Even if justified, favoring delayed over adjuvant radiotherapy 
does not seem sufficient to explain the overall low utilization 
of radiotherapy in post-prostatectomy setting. In a recent US 
nation-wide practice analysis, the use of immediate (ART) and 
delayed (SRT) was relatively stable over time, with only a slight 
increase in delayed RT between 2007 and 2009 (24). Contrary to 
this, another study has reported a minimal shift toward earlier 
radiation after the publication of the ART randomized studies 
(23). These findings together challenge the assertion that the 
underutilization of ART is due to increased use of SRT, and it 
seems safe to state that neither immediate nor delayed radiation 
has been increasingly used despite large trials demonstrating 
benefits. In current practice, some patients are being precluded 
of a potentially curable treatment for PCa after initial radical 
prostatectomy.
Concerns with Radiation Toxicities: How 
Much More evidence is needed?
Radiation toxicities and their impact on the quality of life (20, 
45) might be another deterrent for the use of ART/SRT. This, 
in part, can be explained by EORTC and SWOG trials’ reports 
of increased incidence of late toxicities in the adjuvant RT 
arm (8, 9). In EORTC trial, grade 2 or higher late GU toxicity 
was significantly higher in radiation arm (21.3 vs. 13.5%), but 
late grade 2 GI toxicity rates were similar. Nonetheless, more 
clinically relevant grade 3 side effects were not significantly 
different between the two arms (2.5–5%), and no grade 4 events 
were reported (8). Although the SWOG trial did not report 
graded toxicity, complications were generally more frequent 
in the radiation arm (23.8 vs. 11.9%), mainly due to rectal 
complications (3.3 vs. 0%) and urethral strictures (17.8 vs. 
9.5%) (9). Although ART seems to double the relative risk of 
complications as compared to observation, the absolute rates 
of long-term toxicities remain low, particularly for high grade 
side effects. From a benefit/risk analysis based on these early 
studies, the NNT for improving biochemical relapse rates (1.6 at 
10 years) remains significantly better than the NNH (5 for grade 
2 or higher and 20 for grade 3 or higher) to present any toxicity 
during 10-year follow-up.
Both EORTC and SWOG trials used conventional two-
dimensional radiotherapy planning (e.g., four-field box), which 
does not represent state-of-the-art radiation oncology practice. 
Over the last decade, various and significant technological inno-
vations have been realized in radiation planning and delivery 
(46). The advent of high-precision radiotherapy has positively 
impacted the delivery of lower doses to surrounding normal 
tissues and the subsequent risk of toxicities. With intensity-
modulated radiotherapy (IMRT), even more conformal plan-
ning is feasible compared to three-dimensional radiotherapy 
(3DCRT), translating in improved early GI/GU (47) and late GI 
toxicity profiles (48). Moreover, daily image guidance added to 
IMRT planning for accurate delivery allows prioritizing rectal 
dose constraints over target volume coverage. When tested in a 
recent phase II trial, this technique translated in excellent bio-
chemical control without grade 3–4 acute or late toxicities (45). 
Although longer follow-up is warranted, the implementation of 
modern radiotherapy techniques in the post-prostatectomy set-
ting will likely reflect in declining rates of long-term toxicities and 
subsequent QoL impact, as have indeed been observed in other 
PCa radiotherapy scenarios (49). Whereas no randomized study 
has directly compared the toxicities of conventional vs. high-
precision planning (and it is unlikely to be conducted), Table 1 
summarizes and contrasts the results of benchmark randomized 
trials and contemporary studies employing state-of-the-art radio-
therapy techniques, reporting the toxicity profile of postoperative 
radiotherapy. Despite variations among groups in the definition 
of target volumes, doses, and radiation techniques, a very low 
rate of high grade acute or chronic toxicities is consistent across 
studies. The majority of adverse events are grade 2, and none of 
the available reports have described grade 4 toxicities.
There is very limited literature on the quality of life (QoL) and/
or patient-reported outcomes after postoperative radiotherapy 
(Table 2). Moreover, the methodology for measuring and report-
ing QoL is not uniform, which further limits drawing definite 
conclusions. After radiation, the available longitudinal data show 
a transient decline in GI and GU QoL indicators, particularly 
during the first months. With longer follow-up (e.g., 3–12 months 
after ART/SRT), QoL metrics return to patient’s pre-radiation 
baseline or become comparable to reference values in GI, GU, 
and sexual domains. However, among the studies quantifying 
long-term symptoms and their impact on QoL, the results are 
not fully consistent. In the study by Moinpour et al. (50) report-
ing QoL of SWOG trial’s participants, bowel tenderness and 
urgency were significantly higher in radiation arm (47 vs. 5% at 
6  weeks); however, this negative impact of ART was transient, 
and no difference between treatment arms was present after 
2 years. Pinkawa et al. also report higher rates of bowel bother at 
a follow-up longer than 12 months, although the mean decrease 
in score is 4 points compared to baseline (90 vs. 94) (67). This 
long-term detrimental impact in GI-related QoL has not been 
observed in other studies. The SWOG quality-of-life analysis also 
reported long-term impact on urinary frequency subscale (50), 
where patients reported 15% more frequent urination over the 
follow-up duration (5 years). Again, this effect trend has not been 
observed in other reports. Overall differences between these two 
earlier and the most recent studies could in part be explained by 
TABLe 1 | Summary of post-prostatectomy radiotherapy studies, outcomes, and toxicities.
Study Prospective number of 
patients, median 
follow-up
Technique, total 
dose
bRFR Acute G ≥ 2 
toxicity (%)
Acute G3–4 
toxicity (%)
Late G ≥ 2 
toxicity (%)
Late G3–4 
toxicity (%)
Change 
in eD 
(%)
GU Gi GU Gi GU Gi GU Gi
Thompson et al. (9)/
Moinpour et al. (50)
Yes (RCT) 425, 10.6 years Conventional, 
60–64 Gy
65.1% (ART) vs. 36% (Obs) 
(10 years)
NR NR NR NR 24.3a 3.3a NR NR NR
Bolla et al. (8) Yes (RCT) 1005, 10.6 years Conventional, 60 Gy 60.6% (ART) vs. 41.1%(Obs) 
(10 years)
NR NR NR NR 21.3 2.5 5.3 NR
Wiegel et al. (10) Yes (RCT) 385, 53.7 months Conventional, 60 Gy 72% (ART) vs. 54% (Obs) 
(5 years)
NR NR NR NR 2 1.4 0.5 0 NR
Choo/Pearse et al. 
(51, 52)
Yes 75, 45.1 months 3DCRT, 66 Gy 78.6% (7 years) 12 18 3 3 22.6 8.7 2.8 1.6 NR
Eldredge et al. (53) No 68, 15 months IG-3DCRT, 68.4 Gy 93% (3 years) 15 13 2 0 13.6 5.4 0 3 NR
De Meerleer et al. (54) No 135, 9 months IMRT, 74 Gy 67% (3 years) 28 15 3 0 33.8 16 3 3 NR
Ost et al. (55) No 104, 36 months IMRT, 74 Gy 93% (3 years) 34.6 22 8 0 26 7 4 0 NR
Goenka et al. (48) No 176, 53 months 3DCRT, IMRT, ≥70 Gy 39.9% (5 years) 16.3 9.8 NR 0 17 5.2 6 1.4 27
Shelan et al. (56) No 76, 52 months IMRT, 70 Gy 62.5% (4 years) NR NR NR NR NR NR 4 0 NR
Wong et al. (57) No 50, 18.9 months IG-IMRT, 65 Gy 72.9% (2 years) 8 2 0 0 4 4 0 0 NR
Sandhu et al. (58) Yes 26, NR IG-IMRT, 68 Gy NR 12 4 0 0 NR NR NR NR NR
Cheng et al. (59) No 70, 10.6 months IG-IMRT, 68.8 Gy NR 36 41 0 0 NR NR NR NR NR
Nath et al. (47) No 50, 24 months IG-IMRT, 68 Gy NR 14 8 0 0 16 2 2 0 NR
Deville et al. (60) No 67, 25.5 months IG-IMRT, 70.2 Gy NR 16 46 3 0 24 1.5 9 0 NR
Hunter et al. (61) No 104, 33 months IG-IMRT, 70 Gy NR NR NR NR NR 11.6 0 5.4 0 NR
Chua et al. (62) Yes 75, NR IG-IMRT, 66 Gy NR 30.6 22.6 4 1 NR NR NR NR NR
Cremers et al. (63) No 197, 40 months 3DCRT, 63 and 
58.5 Gy (2.25 Gy/fr)
59% (5 years) NR NR NR NR 29.4 1.5 6 0.6 NR
Cortes-Gonzalez et al. 
(64)
No 184, 48 months 3DCRT, 70 Gy 63% (4 years) NR NR 3 0 NR NR 9 5 NR
Corbin et al. (65) Yes 78, 24 months IMRT, 66.6 Gy NR NR NR NR NR NR NR NR NR NS
van Gysen et al. (66) Yes 64, 24 months IMRT, 66 Gy NR NR NR NR NR NR NR NR NR NS
Berlin et al. (45) Yes 68, 71.2 months IG-IMRT, 66 Gy 72.7% (5 years) 38.2 22 0 0 10.6 12.3 0 0 NS
bRFR, biochemical relapse-free rate; G, grade; G3–4, grade 3–4; GU, genitourinary; GI, gastrointestinal; ED, erectile dysfunction; RCT, randomized controlled trial; 3DCRT, three-dimensional conformal radiation therapy; IG-3DCRT, 
image-guided three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; ART, adjuvant radiotherapy; Obs, observation arm; NR, not reported; NS, non-significant.
aToxicity grade not reported.
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TABLe 2 | Summary of studies on patient-reported QoL indicators.
Study Setting Technique QoL tool Urinary 
domain, mean
Bowel 
domain, 
mean
Sexual 
domain, 
mean
Global health 
domain, mean
Comparator a Difference from comparator Last reported 
measurement 
(months)
Moinpour et al. (50) ART vs. RP 
only
3DCRT SWOG QoL 
Questionnaire
NA NA NA NA Baseline SS in favor of control arm: urinary 
frequency at 60 months, bowel function 
until 24 months, global QoL at 6 weeks
60
SS in favor of radiation arm: global QoL at 
60 months
NS at other time points
Pinkawa et al. (67) SRT/ART 4F Box EPIC Function, 84
Incontinence, 74
Function, 91
Bother, 90
Function, 11 NR Baseline SS in favor of control arm: urinary function 
at 6 weeks, bowel function at 2 months, 
bowel bother at >1 year
NS at other time points
>12
Cremers et al. (63) SRT 3DCRT EPIC Function, 80 Function, 93 Function, 23 NR Reference NS NA
Cortes-Gonzalez 
et al. (64)
SRT + NHT 3DCRT QLQ-C30, 
PR-25
Symptoms, 
24.7b
Symptoms, 
9.4b
Symptoms, 
50.4b
Function, 77.9b Reference NS NA
Corbin et al. (65) SRT/ART IMRT EPIC 26, IPSS Irritations, 86 Function, 89 Function, 36 NR Baseline NS 24
Incontinence, 78
van Gysen et al. 
(66)
SRT/ART IMRT EPIC Function, 82 Function, 94 Function, 14 Physical 
component, 48
Baseline NS 15
Incontinence, 74
Berlin et al. (45) SRT/ART IG-IMRT EPIC Function, 85
Incontinence, 76
Function, 94
Bother, 90
Function, 25
Bother, 58
NR Baseline SS in favor of control arm: urinary irritation 
at 5 weeks, bowel function at 3 months, 
sexual function at 3 months
NS at other time points
60
QoL, quality of life; ART, adjuvant radiation therapy; RP, radical prostatectomy; SRT, salvage radiation therapy; NHT, neoadjuvant hormone therapy; 3DCRT, three-dimensional conformal radiation therapy; 4F, four field; IMRT, intensity-
modulated radiation therapy; NA, not applicable; NR, not reported; NS, not significant; SS, statistically significant.
aReference: reference values in age-matched healthy population. Baseline: patient’s pre-RT baseline.
bAccording to QLQ-C30 PR-25, higher mean for functional and general health domains shows higher functioning and lower mean for symptoms demonstrates less symptom burden.
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the fact that the former correspond to the pre-IMRT and image-
guidance era.
The impact of ART/SRT on sexual function represents a 
particular concern influenced by the low residual function post-
prostatectomy. The latter also translates into challenges in evaluat-
ing the potential superimposed impact of ART/SRT on this QoL 
domain. Nonetheless, most of the studies that have evaluated this 
area have shown absence of ART/SRT impact on residual erectile 
function (see Table  2). This indeed contrasts with evidence of 
RT as primary treatment for localized disease, where a negative 
long-term impact has been reported (68). However, a possible 
explanation for this difference could be the prescribed doses 
between the two settings. Interestingly, an improvement trend of 
“sexual bother” subscale with time has been shown despite stabil-
ity of sexual function scores, in keeping with patients getting used 
to a steady level of sexual functioning (45).
As an interesting corollary of these findings, the global quality 
of life was only transiently lower at 6 weeks in the SWOL QoL 
study, despite radiation toxicities and subsequent negative impact 
on GI- and GU-related QoL domains. In fact, it remained higher 
at 5 years for patients receiving ART as compared to control group 
(50). This in part could be explained by the effect of improved dis-
ease control on overall QoL in the RT arm. These latter observa-
tions serve to reinforce the complexity of QoL-related outcomes 
and studies. At any rate, considering the well-known mismatch 
in perception of QoL outcomes between physicians and patients 
(69), additional effort should be made by practitioners to convey 
unbiased information, which is more consistent with current 
evidence showing absence of detrimental effect (or even overall 
improvement) on QoL domains with the use of modern state-of-
the-art post-prostatectomy RT.
COnCLUSiOn AnD FUTURe STePS
Postoperative adjuvant and salvage radiotherapy are effective and 
safe treatments in patients with high-risk factors or rising PSA 
after prostatectomy, respectively. Their underutilization might 
have several reasons, including concerns with overtreatment 
and radiation-related side effects. The current available data on 
toxicity demonstrate increased incidence of acute and long-term 
grade 2 events, but no significant increase of grade 3–4 long-term 
side effects with the use of ART/SRT. Although patients’ quality of 
life is affected transiently, it returns to pre-radiotherapy baseline 
during the first year after therapy. Despite the lack of randomized 
data comparing conventional with modern radiation techniques 
and lack of long-term follow-up of the latter, studies are consist-
ent in suggesting an improved therapeutic index with the use 
of image-guided high-precision radiation, mainly due to better 
sparing of organs-at-risk translating into decreased toxicity rates. 
With the use of adjuvant radiation, a proportion of patients will 
be overtreated; however, present evidence does not seem robust 
enough to support similar effectiveness between delayed and 
adjuvant radiotherapy, and the latter should continue to represent 
the standard of care approach.
The literature on QoL and patient-reported outcomes after 
post-prostatectomy RT remains scarce, and continuous efforts 
in gathering prospective QoL data using validated tools seems 
necessary. Integration of QoL outcomes into both decision-
making process and evaluation of treatments’ impact on survival 
outcomes remains an unmet challenge (70).
In conclusion, concerns with toxicities and/or impact in QoL 
outcomes should not preclude patients from gaining the proven 
benefits of either ART or SRT. Pending the results of prospective 
studies comparing adjuvant vs. early salvage radiotherapy, the 
former should represent the standard approach during shared 
decision-making process between physicians and patients for 
treatment individualization in men with localized prostate cancer 
after radical prostatectomy.
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